Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.

JCO Precis Oncol · 2022 · PMC8820927 · PMID 35108036

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significanceP = .075so close (0.05 < p ≤ 0.1)

Median PFS improved by > 10 months in patients with pathogenic mutations compared with nonactionable variants, although this did not reach statistical significance (15.1 v 4.2 months; P = .075).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.